New York investment firm Altitude Investment Management on Thursday announced a USD2.4m strategic investment in EMMAC Life Sciences Limited.
This is its first investment in a European cannabis company.
Headquartered in the UK, EMMAC combines the latest science and research with cutting-edge cultivation, extraction and production.
Altitude's participation is part of a GBP11m financing, which will be used by EMMAC to close pending acquisitions as well as support collaborative research efforts focused on medical cannabis.
Through the financing, EMMAC will import medical cannabis into the UK and manufacture EU GMP products. It has established a research collaboration with Imperial College London to investigate cannabis-based medicinal products designed to directly benefit patients. The initial focus will be research on therapeutic products for chronic pain, spasticity and cancer.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886